Antiplatelet and Anticoagulant Therapy in the 2025 ACC/AHA Guideline for Acute Coronary Syndromes: Key Recommendations [0.03%]
2025年ACC / AHA急性冠状动脉综合征指南中的抗血小板和抗凝治疗：关键推荐意见
Behnood Bikdeli,Francisco Ujueta,Sina Rashedi et al.
Behnood Bikdeli et al.
Carolyn S P Lam,Erica S Spatz
Carolyn S P Lam
Celina M Yong,Robert M Califf
Celina M Yong
The Long-Awaited American ACS Guideline: Closer to a Universal Document [0.03%]
姗姗来迟的美国ACS指南：更接近于一部通用文件
Valentin Fuster,Borja Ibanez
Valentin Fuster
Elliott M Antman,Eugene Braunwald
Elliott M Antman
Harlan M Krumholz
Harlan M Krumholz
Estimating the Global Impact of Lp(a) Across Different Thresholds and Populations: Challenges for Personalized Risk Prediction [0.03%]
基于不同阈值和人群估计Lp(a)的全球影响及精准分层预测所面临的挑战
Ron Blankstein,Adam N Berman,Arthur Shiyovich et al.
Ron Blankstein et al.
Global Variation in Lipoprotein(a) Levels Among Patients With Coronary Heart Disease: Insights From the INTERASPIRE Study and Implications for Emerging Lp(a)-Lowering Therapies [0.03%]
冠心病患者的脂蛋白(a)水平的全球差异：来自INTERASPIRE研究的结果及对新兴降脂蛋白(a)治疗方式的意义
Fotios Barkas,Julia Brandts,Dirk De Bacquer et al.
Fotios Barkas et al.
Background: Lipoprotein(a) [Lp(a)] is a common risk factor for atherosclerotic cardiovascular disease, potentially more atherogenic per particle than low-density lipoprotein. An estimated 1.5 billion individuals globally ...
Lipoprotein(a) and High-Risk Coronary Plaque: Dawn of a New Era in Assessment and Management of Vulnerable Plaque [0.03%]
脂蛋白(a)与高危冠状动脉斑块：易损斑块评估和管理的新纪元
Seong-Bong Wee,Jung-Min Ahn,Do-Yoon Kang et al.
Seong-Bong Wee et al.